Amneal Pharmaceuticals
(NASDAQ) AMRX
Amneal Pharmaceuticals Financials at a Glance
Market Cap
$3.72B
Revenue (TTM)
$3.02B
Net Income (TTM)
$72.06M
EPS (TTM)
$0.22
P/E Ratio
53.43
Dividend
$0.00
Beta (Volatility)
1.09 (Average)
Dividend
$0.00
Beta (Volatility)
1.09 (Average)
Price
$11.92
Volume
53,800
Open
$12.23
Price
$11.92
Volume
53,800
Open
$12.23
Previous Close
$11.92
Daily Range
$11.88 - $12.24
52-Week Range
$6.68 - $15.42
Dividend
$0.00
Beta (Volatility)
1.09 (Average)
Price
$11.92
Volume
53,800
Open
$12.23
Previous Close
$11.92
Daily Range
$11.88 - $12.24
52-Week Range
$6.68 - $15.42
AMRX News
AMRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Amneal Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
8,500
CEO
Chintu Patel, PhD; Chirag K. Patel, PhD
Website
www.amneal.comHeadquarters
Bridgewater, NJ 08807, US
AMRX Financials
Key Financial Metrics (TTM)
Gross Margin
37%
Operating Margin
11%
Net Income Margin
2%
Return on Equity
0%
Return on Capital
12%
Return on Assets
2%
Earnings Yield
1.87%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.72B
Shares Outstanding
314.63M
Volume
53.80K
Short Interest
0.00%
Avg. Volume
2.59M
Financials (TTM)
Gross Profit
$1.14B
Operating Income
$423.09M
EBITDA
$603.87M
Operating Cash Flow
$339.99M
Capital Expenditure
$70.06M
Free Cash Flow
$269.93M
Cash & ST Invst.
$310.87M
Total Debt
$2.74B
Amneal Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$814.32M
+11.5%
Gross Profit
$297.19M
+13.1%
Gross Margin
36.50%
N/A
Market Cap
$3.72B
N/A
Market Cap/Employee
$448.44K
N/A
Employees
8,300
N/A
Net Income
$35.08M
+212.9%
EBITDA
$160.70M
+42.9%
Quarterly Fundamentals
Net Cash
$2.43B
+2.2%
Accounts Receivable
$939.87M
+21.2%
Inventory
$606.30M
-1.0%
Long Term Debt
$2.71B
+20.5%
Short Term Debt
$21.58M
-93.7%
Return on Assets
1.96%
N/A
Return on Invested Capital
11.66%
N/A
Free Cash Flow
$87.15M
-8.3%
Operating Cash Flow
$130.31M
+10.4%